T-cell Therapy in Patients With PML

Phase 2RecruitingNCT06990087

Hannover Medical School23 enrolled

Overview

There is no approved standard treatment für progressive multifocal leukoencephalopathy (PML). The sponsor of the study is developing a new treatment. For this reason, the investigational medicinal product (IMP) called 'human allogenic HPyV-2-specific T cells' is to be tested in this study. The sponsor wants to find out whether the IMP is safe, influences the neurological status and improves the quality of the life of patients . It is to be investigated whether the IMP can be used to treat the disease and whether it could have an advantage over the standard therapy in terms of survival rate.

Progressive multifocal leukoencephalopathy (PML) is a severe infection of the central nervous system (CNS) caused by reactivation of human polyoma virus 2 (HPyV-2). HPyV-2 usually produces asymptomatic, lifelong persistent or latent infection in the general population. However, in patients with long lasting and profound impairment of cellular immunity, HPyV-2 can reactivate from latency leading to lytic infection of CNS glial cells and thus to encephalitis PML. PML is usually fatal or at least associated with severe disability which makes it a relevant target for the search of appropriate therapeutic options. The investigational medicinal products (IMPs) under test are fresh and cryopreserved allogeneic HPyV-2-specific T-lymphocyte apheresis concentrates. Each patient will receive one HPyV-2-specific T-lymphocyte fresh product and two additional cryopreserved products from the same manufacture with the same dose 2 and 6 weeks after baseline, respectively. This is the first controlled clinical trial to treat patients suffering from PML with this specific methodology of T-cell therapy. The currently available evidence of safety and efficacy is only based on a small series of individual cases treated on a compassionate use basis. This study aims to generate data on safety and first evidence of efficacy within a standardized clinical trial protocol complying to ICH-GCP principles.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults\* aged ≥ 18 years with PML (diagnosed ≤ 60 days before screening) associated with one or more of the following risk factors: lymphoproliferative diseases, immunosuppressive therapy, or lymphopenia * Signed written informed consent from subject and/or legal representative * HPyV-2 detection in CSF by PCR analysis or in brain biopsy Exclusion Criteria: * PML caused by HIV * PML caused by natalizumab * PML occurring within five 5 years after hematopoietic stem-cell transplantation or CAR T cell therapy, or resulting from chronic lymphocytic leukemia (CLL) * Patients who are unable to follow the study protocol, either on their own or with the support of a reliable representative, will be excluded * Pregnancy or breastfeeding * Currently receiving chemotherapy * Present (within 2 weeks before screening visit) and continuous treatment with immune checkpoint inhibition therapy * Severe infections other than PML (e.g. sepsis, pneumonia) * Hypersensitivity to any of the components of the medications used * Inability to undergo MRI examination (e.g. implanted incompatible medical devices, claustrophobia) * Participation in another clinical trial (other investigational drugs or devices at the time of enrolment or within 30 days prior to enrolment)

Locations (6)

LMU Klinikum Campus Großhadern

München, Bavaria, Germany

NOT_YET_RECRUITING

Universitätsklinikum Marburg

Marburg, Hesse, Germany

NOT_YET_RECRUITING

Hannover Medical School

Hanover, Lower Saxony, Germany

RECRUITING

Universitätsklinikum Düsseldorf

Düsseldorf, North Rhine-Westphalia, Germany

NOT_YET_RECRUITING

Universitätsklinikum Essen

Essen, North Rhine-Westphalia, Germany

NOT_YET_RECRUITING

Universitätsklinikum Schleswig-Holstein

Kiel, Schleswig-Holstein, Germany

NOT_YET_RECRUITING

Outcomes

Primary Outcomes

Demonstrate efficacy of treatment

Determine proportion of patients surviving 6 months (overall survival) since diagnosis.

Time frame: 6 months after diagnosis

Secondary Outcomes

Safety assessment

Recording of AEs, SAEs, AE of special interest (GvHD, allergic reactions).

Time frame: During 12 months from baseline

Safety assessment

Determine proportion of patients surviving 12 months (via telephone interview).

Time frame: At 12 months from baseline

Assessment of potential inflammatory safety concerns

Laboratory examination of differential blood count (cells/microliter).